董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward Andrle | 男 | Director | 68 | 15.00万美元 | 20.73 | 2026-04-03 |
| Paul Buckman | 男 | Chairman and Director | 70 | 19.90万美元 | 31.70 | 2026-04-03 |
| Jeffrey Mathiesen | 男 | Director | 65 | 15.30万美元 | 28.32 | 2026-04-03 |
| David Rosa | 男 | Chief Executive Officer and Director and President | 61 | 115.44万美元 | 176.97 | 2026-04-03 |
| Jason Mills | 男 | Director | 53 | 未披露 | 未持股 | 2026-04-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ronald McClurg | 男 | Chief Financial Officer | 67 | 52.38万美元 | 55.38 | 2026-04-03 |
| Mark Christianson | 男 | Business Development Director, Medical Sales Liaison | 58 | 26.08万美元 | 未持股 | 2026-04-03 |
| Steve Mertens | 男 | Chief Technology Officer | 63 | 45.77万美元 | 未持股 | 2026-04-03 |
| David Rosa | 男 | Chief Executive Officer and Director and President | 61 | 115.44万美元 | 176.97 | 2026-04-03 |
| Christopher Volker | 男 | Chief Operating Officer | 53 | 68.74万美元 | 26.43 | 2026-04-03 |
| Emily Johns | 女 | Chief Administrative Officer and General Counsel | 35 | 未披露 | 未持股 | 2026-04-03 |
董事简历
中英对照 | 中文 | 英文- Edward Andrle
-
Edward Andrle自2015年10月起担任LivaNova战略&业务开发高级副总裁。Andrle之前曾自2010年9月起担任Sorin战略&业务开发副总裁。加入Sorin之前，Andrle曾在医疗设备行业任职，最先是在大型美国公司任职，例如Baxter and Boston Scientific；之前曾担任初创公司，例如Teramed, Inc.（专攻腔内带膜支架）、Myocor, Inc.（专注于体外循环）、以及StarFire Medical, Inc.（专注于神经与血管技术）企业家和首席执行官。Andrle持有Stanford Graduate School of Business工商管理硕士学位； the University of Notre Dame化学工程理学学士学位。
Edward Andrle has served as a member of the Board since February 2020. Since February 2023, Mr. Andrle has served as the Chairman of the Board and Co Founder of Arcos Interventional, Inc. a structural heart company. Prior to that, he most recently served as the general manager of Neuromodulation of LivaNova PLC (Nasdaq: LIVN), a publicly traded medical device company, from January 2018 to January 2020, and as senior vice president of strategy and biness development of LivaNova PLC from September 2015 to January 2018. Prior to these roles, Mr. Andrle served as vice president of biness development and strategy of Sorin S.p.A from 2010 to September 2015, when Sorin S.p.A. was merged with Cyberonics, Inc. to become LivaNova PLC. Prior to joining Sorin, he co founded three medical device companies: Myocor Inc., TERAMED Inc. and StarFire Medical Inc. All three companies re eventually acquired. He also held executive positions with Boston Scientific, Inc. (NYSE: BSX) and Baxter International, Inc. (NYSE: BAX), leading large product portfolios in cardiovascular and dialysis. Mr. Andrle received his MBA from Stanford Graduate School of Biness and his B.S. in Chemical Engineering from the University of Notre Dame. - Edward Andrle自2015年10月起担任LivaNova战略&业务开发高级副总裁。Andrle之前曾自2010年9月起担任Sorin战略&业务开发副总裁。加入Sorin之前，Andrle曾在医疗设备行业任职，最先是在大型美国公司任职，例如Baxter and Boston Scientific；之前曾担任初创公司，例如Teramed, Inc.（专攻腔内带膜支架）、Myocor, Inc.（专注于体外循环）、以及StarFire Medical, Inc.（专注于神经与血管技术）企业家和首席执行官。Andrle持有Stanford Graduate School of Business工商管理硕士学位； the University of Notre Dame化学工程理学学士学位。
- Edward Andrle has served as a member of the Board since February 2020. Since February 2023, Mr. Andrle has served as the Chairman of the Board and Co Founder of Arcos Interventional, Inc. a structural heart company. Prior to that, he most recently served as the general manager of Neuromodulation of LivaNova PLC (Nasdaq: LIVN), a publicly traded medical device company, from January 2018 to January 2020, and as senior vice president of strategy and biness development of LivaNova PLC from September 2015 to January 2018. Prior to these roles, Mr. Andrle served as vice president of biness development and strategy of Sorin S.p.A from 2010 to September 2015, when Sorin S.p.A. was merged with Cyberonics, Inc. to become LivaNova PLC. Prior to joining Sorin, he co founded three medical device companies: Myocor Inc., TERAMED Inc. and StarFire Medical Inc. All three companies re eventually acquired. He also held executive positions with Boston Scientific, Inc. (NYSE: BSX) and Baxter International, Inc. (NYSE: BAX), leading large product portfolios in cardiovascular and dialysis. Mr. Andrle received his MBA from Stanford Graduate School of Biness and his B.S. in Chemical Engineering from the University of Notre Dame.
- Paul Buckman
-
Paul Buckman目前是LivaNova PLC TMVR的总经理。在加入Livanova之前，Buckman先生于2013年9月至2017年3月担任Conventus Orthopaedics（一家位于明尼苏达州的公司，专门从事关节周围骨折固定）的首席执行官。Buckman从2012年2月到2013年9月担任SentreHeart，Inc.（一家医疗技术公司，专注于关闭各种解剖结构）首席执行官。此前，Buckman从2008年9月到2012年2月担任Pathway Medical Technologies，Inc.（一家医疗设备公司，专注于治疗外周动脉疾病）首席执行官和董事长；2006年12月至2008年9月；2004年8月至2006年12月，担任上市多元化医疗产品公司圣犹达医疗公司心脏病部总裁；以及EV3LLC董事会主席兼首席执行官，从2001年1月到2004年1月，Buckman先生创立了一家总部位于明尼苏达州的医疗器械公司，专注于血管内疗法，并将其发展成为一家价值8000万美元的企业。巴克曼先生在医疗设备行业工作了30多年，包括在SCIMED Life Systems，Inc.和波士顿科学国际有限公司（一家公开上市的医疗设备制造商）工作了10年，在那里他担任过几个执行职位，直到2000年1月成为波士顿科学公司心脏病部门的总裁。Buckman先生目前还担任NeuroOne，Inc.的董事。Chariman，Ablative Solutions，Inc.，Activortho，Aortica，Inc.，Dyamx，Inc.和MiroMatrix，Inc.（董事长）。他此前曾担任Conventus Orthopaedics公司、Caisson Interventional LLC、Velocimed公司的董事，在那里他曾担任Endicor公司、Microvena公司、Sunshine Heart公司（上市早期医疗设备公司）、Micro Therapeutics公司的联席创始人。除了筹集了超过5亿美元的私人资本外，巴克曼担任首席执行官、董事或联合创始人的公司的总退出价值约为28亿美元。Buckman先生在西密歇根大学（Western Michigan University）获得工商管理与财务硕士学位和工商管理学士学位。
Paul Buckman has served as Chairman of the Board since Augt 2017, and served as chairman of the board of NeuroOne, Inc., from October 2016 until December 2019. Since April 2024, Mr. Buckman has served as Chief Executive Officer of Rhythmlink International LLC. Mr. Buckman previoly served as President of Advanced Circulatory Support for LivaNova PLC (Nasdaq: LIVN) and as President, North America and the general manager of structural heart for LivaNova PLC beginning in April 2017. Prior to joining LivaNova PLC, Mr. Buckman served as chief executive officer of Convent Orthopaedics, a Minnesota based company specializing in peri articular bone fracture fixation, from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology company foced on closure of vario anatomic structures, from February 2012 to September 2013. Previoly, Mr. Buckman served as chief executive officer and chairman of Pathway Medical Technologies, Inc., a medical device company foced on treatment of peripheral arterial disease, from September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer of drug eluting stents, from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc., a publicly traded diversified medical products company, from Augt 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC, a Minnesota based medical device company foced on endovascular therapies that Mr. Buckman founded and developed into an $80 million biness, from January 2001 to January 2004. Mr. Buckman has worked in the medical device indtry for over 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation (NYSE: BSX), a publicly traded medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for Heli Medical Technologies, Inc. n/k/a Solana Company (Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho Inc., a privately held company, Shoulder Innovations, Inc., a privately held company, Rhythmlink International LLC, a privately held company, and as chairman of Miromatrix, Inc. He previoly served as a director of Aortica, Inc., DyaMX, Inc., Convent Orthopaedics, Caisson Interventional LLC, Velocimed, Inc., where he was a co founder, EndiCor, Inc., Microvena, Inc., Sunshine Heart, Inc., n/k/a Nullis, Inc. (Nasdaq: NU), a publicly held early stage medical device company, NexGen Medical, and Micro Therapeutics, Inc. Mr. Buckman received a Master's degree in Biness Administration and Finance and a B.A. degree in Biness Administration from stern Michigan University. - Paul Buckman目前是LivaNova PLC TMVR的总经理。在加入Livanova之前，Buckman先生于2013年9月至2017年3月担任Conventus Orthopaedics（一家位于明尼苏达州的公司，专门从事关节周围骨折固定）的首席执行官。Buckman从2012年2月到2013年9月担任SentreHeart，Inc.（一家医疗技术公司，专注于关闭各种解剖结构）首席执行官。此前，Buckman从2008年9月到2012年2月担任Pathway Medical Technologies，Inc.（一家医疗设备公司，专注于治疗外周动脉疾病）首席执行官和董事长；2006年12月至2008年9月；2004年8月至2006年12月，担任上市多元化医疗产品公司圣犹达医疗公司心脏病部总裁；以及EV3LLC董事会主席兼首席执行官，从2001年1月到2004年1月，Buckman先生创立了一家总部位于明尼苏达州的医疗器械公司，专注于血管内疗法，并将其发展成为一家价值8000万美元的企业。巴克曼先生在医疗设备行业工作了30多年，包括在SCIMED Life Systems，Inc.和波士顿科学国际有限公司（一家公开上市的医疗设备制造商）工作了10年，在那里他担任过几个执行职位，直到2000年1月成为波士顿科学公司心脏病部门的总裁。Buckman先生目前还担任NeuroOne，Inc.的董事。Chariman，Ablative Solutions，Inc.，Activortho，Aortica，Inc.，Dyamx，Inc.和MiroMatrix，Inc.（董事长）。他此前曾担任Conventus Orthopaedics公司、Caisson Interventional LLC、Velocimed公司的董事，在那里他曾担任Endicor公司、Microvena公司、Sunshine Heart公司（上市早期医疗设备公司）、Micro Therapeutics公司的联席创始人。除了筹集了超过5亿美元的私人资本外，巴克曼担任首席执行官、董事或联合创始人的公司的总退出价值约为28亿美元。Buckman先生在西密歇根大学（Western Michigan University）获得工商管理与财务硕士学位和工商管理学士学位。
- Paul Buckman has served as Chairman of the Board since Augt 2017, and served as chairman of the board of NeuroOne, Inc., from October 2016 until December 2019. Since April 2024, Mr. Buckman has served as Chief Executive Officer of Rhythmlink International LLC. Mr. Buckman previoly served as President of Advanced Circulatory Support for LivaNova PLC (Nasdaq: LIVN) and as President, North America and the general manager of structural heart for LivaNova PLC beginning in April 2017. Prior to joining LivaNova PLC, Mr. Buckman served as chief executive officer of Convent Orthopaedics, a Minnesota based company specializing in peri articular bone fracture fixation, from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology company foced on closure of vario anatomic structures, from February 2012 to September 2013. Previoly, Mr. Buckman served as chief executive officer and chairman of Pathway Medical Technologies, Inc., a medical device company foced on treatment of peripheral arterial disease, from September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer of drug eluting stents, from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc., a publicly traded diversified medical products company, from Augt 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC, a Minnesota based medical device company foced on endovascular therapies that Mr. Buckman founded and developed into an $80 million biness, from January 2001 to January 2004. Mr. Buckman has worked in the medical device indtry for over 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation (NYSE: BSX), a publicly traded medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for Heli Medical Technologies, Inc. n/k/a Solana Company (Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho Inc., a privately held company, Shoulder Innovations, Inc., a privately held company, Rhythmlink International LLC, a privately held company, and as chairman of Miromatrix, Inc. He previoly served as a director of Aortica, Inc., DyaMX, Inc., Convent Orthopaedics, Caisson Interventional LLC, Velocimed, Inc., where he was a co founder, EndiCor, Inc., Microvena, Inc., Sunshine Heart, Inc., n/k/a Nullis, Inc. (Nasdaq: NU), a publicly held early stage medical device company, NexGen Medical, and Micro Therapeutics, Inc. Mr. Buckman received a Master's degree in Biness Administration and Finance and a B.A. degree in Biness Administration from stern Michigan University.
- Jeffrey Mathiesen
-
Jeffrey Mathiesen自2017年8月起担任董事会成员，并于2017年4月至2019年12月担任NeuroOne，Inc.的董事。此外，Mathiesen先生自2020年3月以来一直担任Panbela Therapeutics，Inc.的副主席兼首席独立董事，自2015年以来一直担任Panbela Therapeutics，Inc.的董事兼审计委员会主席。纳斯达克:PBLA，一家上市的生物制药公司，开发胰腺疾病的疗法。自2020年6月以来，马蒂森先生一直担任Helius Medical Technologies, Inc.（纳斯达克市场代码:HSDT）的董事会成员，该公司是一家上市医疗设备公司，致力于开发专注于神经健康的非侵入性平台技术，从2018年到2020年，他曾担任Eneura，Inc.的董事会成员，该公司是一家私营医疗技术公司，为偏头痛的急性治疗和预防提供治疗。Mathiesen先生曾担任Teewinot Life Sciences Corporation首席执行官的顾问，该公司是一家私人控股的全球领导者，致力于消费和制药产品的大麻素及其衍生物的生物合成开发和生产，从2019年10月至2019年12月，并于2019年3月至2019年10月担任首席财务官。2020年8月，Teewinot Life Insurance Sciences根据《美国破产法典》第11章提交了自愿请愿书。Mathiesen先生曾于2015年至2018年担任Gemphire Therapeutics Inc.的首席财务官，该公司于2020年1月被NeuroBoPharmaceuticals，Inc.（纳斯达克市场代码:NRBO）收购，这是一家上市的临床阶段生物制药公司，为心脏代谢疾病患者开发疗法，并担任Sunshine Heart的首席财务官，从2011年到2015年，Inc.（纳斯达克市场代码:CHFS）是一家上市的早期医疗设备公司。Mathiesen先生在南达科他州大学获得会计学士学位，是一名注册会计师。
Jeffrey Mathiesen has served as a member of the Board since Augt 2017, and served as a director of NeuroOne, Inc., from April 2017 until December 2019. Since June 2021, Mr. Mathiesen has served as Chief Financial Officer, Treasurer and Secretary of Heli Medical Technologies, Inc. ("Heli") n/k/a Solana Company (Nasdaq: HSDT), a publicly traded medical device company, developing noninvasive platform technologies foced on neurological llness as ll as a digital asset treasury ("DAT") dedicated to acquiring and holding Solana. He served as director of Heli from May 2022 through October 2025 and previoly served as director and Audit Committee Chair from June 2020 through June 2021. Additionally, Mr. Mathiesen has served as Vice Chair and Lead Independent Director from March 2020 until April 2025, and as director and Audit Committee Chair, from 2015 until April 2025, of Panbela Therapeutics, Inc. (OTCQB: PBLA), a publicly traded biopharmaceutical company developing therapies for pancreatic diseases, and served as a director and Audit Committee Chair of Healthcare Triangle, Inc. (Nasdaq: HCTI), a publicly traded provider of cloud and data transformation platform and solutions for healthcare and life sciences, from March 2022 to December 2022, and as a director of eNeura, Inc., a privately held medical technology company providing therapy for both acute treatment and prevention of migraine, from 2018 to 2020. Mr. Mathiesen served as advisor to the chief executive officer of Teewinot Life Sciences Corporation, a privately held global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products, from October 2019 to December 2019, and served as chief financial officer from March 2019 to October 2019. In Augt 2020, Teewinot Life Insurance Sciences filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota. - Jeffrey Mathiesen自2017年8月起担任董事会成员，并于2017年4月至2019年12月担任NeuroOne，Inc.的董事。此外，Mathiesen先生自2020年3月以来一直担任Panbela Therapeutics，Inc.的副主席兼首席独立董事，自2015年以来一直担任Panbela Therapeutics，Inc.的董事兼审计委员会主席。纳斯达克:PBLA，一家上市的生物制药公司，开发胰腺疾病的疗法。自2020年6月以来，马蒂森先生一直担任Helius Medical Technologies, Inc.（纳斯达克市场代码:HSDT）的董事会成员，该公司是一家上市医疗设备公司，致力于开发专注于神经健康的非侵入性平台技术，从2018年到2020年，他曾担任Eneura，Inc.的董事会成员，该公司是一家私营医疗技术公司，为偏头痛的急性治疗和预防提供治疗。Mathiesen先生曾担任Teewinot Life Sciences Corporation首席执行官的顾问，该公司是一家私人控股的全球领导者，致力于消费和制药产品的大麻素及其衍生物的生物合成开发和生产，从2019年10月至2019年12月，并于2019年3月至2019年10月担任首席财务官。2020年8月，Teewinot Life Insurance Sciences根据《美国破产法典》第11章提交了自愿请愿书。Mathiesen先生曾于2015年至2018年担任Gemphire Therapeutics Inc.的首席财务官，该公司于2020年1月被NeuroBoPharmaceuticals，Inc.（纳斯达克市场代码:NRBO）收购，这是一家上市的临床阶段生物制药公司，为心脏代谢疾病患者开发疗法，并担任Sunshine Heart的首席财务官，从2011年到2015年，Inc.（纳斯达克市场代码:CHFS）是一家上市的早期医疗设备公司。Mathiesen先生在南达科他州大学获得会计学士学位，是一名注册会计师。
- Jeffrey Mathiesen has served as a member of the Board since Augt 2017, and served as a director of NeuroOne, Inc., from April 2017 until December 2019. Since June 2021, Mr. Mathiesen has served as Chief Financial Officer, Treasurer and Secretary of Heli Medical Technologies, Inc. ("Heli") n/k/a Solana Company (Nasdaq: HSDT), a publicly traded medical device company, developing noninvasive platform technologies foced on neurological llness as ll as a digital asset treasury ("DAT") dedicated to acquiring and holding Solana. He served as director of Heli from May 2022 through October 2025 and previoly served as director and Audit Committee Chair from June 2020 through June 2021. Additionally, Mr. Mathiesen has served as Vice Chair and Lead Independent Director from March 2020 until April 2025, and as director and Audit Committee Chair, from 2015 until April 2025, of Panbela Therapeutics, Inc. (OTCQB: PBLA), a publicly traded biopharmaceutical company developing therapies for pancreatic diseases, and served as a director and Audit Committee Chair of Healthcare Triangle, Inc. (Nasdaq: HCTI), a publicly traded provider of cloud and data transformation platform and solutions for healthcare and life sciences, from March 2022 to December 2022, and as a director of eNeura, Inc., a privately held medical technology company providing therapy for both acute treatment and prevention of migraine, from 2018 to 2020. Mr. Mathiesen served as advisor to the chief executive officer of Teewinot Life Sciences Corporation, a privately held global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products, from October 2019 to December 2019, and served as chief financial officer from March 2019 to October 2019. In Augt 2020, Teewinot Life Insurance Sciences filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota.
- David Rosa
-
David Rosa，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会提名委员会主席。Rosa先生自2017年7月起担任NeuroOne Medical技术公司（“NeuroOne”）（纳斯达克：NMTC）的首席执行官、总裁和董事，并于2016年10月至2019年12月NeuroOne，Inc.与NeuroOne合并并入NeuroOne期间担任NeuroOne，Inc.的首席执行官和董事。NeuroOne是NeuroOne的全资子公司。NeuroOne致力于为患有癫痫、帕金森病、肌张力障碍、特发性震颤、背部手术失败导致的慢性疼痛和其他相关神经系统疾病的患者提供脑电图记录、脑刺激和消融解决方案的微创和高清晰度解决方案，这些解决方案可能会改善患者的预后并降低手术成本。2009年11月至2015年11月，Rosa先生担任Sunshine Heart，Inc.，n/k/a CHF Solutions，Inc.（纳斯达克：CHFS）的首席执行官兼总裁，这是一家上市的早期医疗设备公司。从2008年到2009年11月，他担任Milksmart公司的首席执行官，该公司是一家专门为动物提供医疗设备的公司。2004年至2008年，罗萨先生在圣犹达医疗公司担任心脏外科和心脏病学全球营销副总裁。他是Biotricity Inc.（纳斯达克：BTCY）和Healthcare Triangle, Inc.（纳斯达克：HCTI）董事会的董事。罗萨先生是芬兰私营公司Neuro Event Labs的董事长，也是马里兰州贝塞斯达私营公司SYNAPS Dx的顾问委员会成员。
David Rosa has served as one of directors and Chair of Board's Nominating Committee since November 2021. Mr. Rosa has served as the Chief Executive Officer, President and a director of NeuroOne Medical Technologies Corporation, or NeuroOne (Nasdaq: NMTC), since July 2017 and served as Chief Executive Officer and a director of NeuroOne, Inc., formerly its wholly owned subsidiary, from October 2016 until December 2019, when NeuroOne, Inc. merged with and into NeuroOne. NeuroOne is committed to providing minimally invasive and hi definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. From November 2009 to November 2015, Mr. Rosa served as the Chief Executive Officer and President of Sunshine Heart, Inc., n/k/a CHF Solutions, Inc. (Nasdaq: CHFS), a publicly held early stage medical device company. From 2008 to November 2009, he served as Chief Executive Officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served as the Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. He serves as a director on the board of directors of Biotricity Inc. (Nasdaq:BTCY) and Healthcare Triangle, Inc. (Nasdaq:HCTI). Mr. Rosa previoly served as Chairman of Neuro Event Labs, a privately held company in Finland, and is an Advisory Board member of SYNAPS Dx, a privately held company in Bethesda, Maryland. - David Rosa，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会提名委员会主席。Rosa先生自2017年7月起担任NeuroOne Medical技术公司（“NeuroOne”）（纳斯达克：NMTC）的首席执行官、总裁和董事，并于2016年10月至2019年12月NeuroOne，Inc.与NeuroOne合并并入NeuroOne期间担任NeuroOne，Inc.的首席执行官和董事。NeuroOne是NeuroOne的全资子公司。NeuroOne致力于为患有癫痫、帕金森病、肌张力障碍、特发性震颤、背部手术失败导致的慢性疼痛和其他相关神经系统疾病的患者提供脑电图记录、脑刺激和消融解决方案的微创和高清晰度解决方案，这些解决方案可能会改善患者的预后并降低手术成本。2009年11月至2015年11月，Rosa先生担任Sunshine Heart，Inc.，n/k/a CHF Solutions，Inc.（纳斯达克：CHFS）的首席执行官兼总裁，这是一家上市的早期医疗设备公司。从2008年到2009年11月，他担任Milksmart公司的首席执行官，该公司是一家专门为动物提供医疗设备的公司。2004年至2008年，罗萨先生在圣犹达医疗公司担任心脏外科和心脏病学全球营销副总裁。他是Biotricity Inc.（纳斯达克：BTCY）和Healthcare Triangle, Inc.（纳斯达克：HCTI）董事会的董事。罗萨先生是芬兰私营公司Neuro Event Labs的董事长，也是马里兰州贝塞斯达私营公司SYNAPS Dx的顾问委员会成员。
- David Rosa has served as one of directors and Chair of Board's Nominating Committee since November 2021. Mr. Rosa has served as the Chief Executive Officer, President and a director of NeuroOne Medical Technologies Corporation, or NeuroOne (Nasdaq: NMTC), since July 2017 and served as Chief Executive Officer and a director of NeuroOne, Inc., formerly its wholly owned subsidiary, from October 2016 until December 2019, when NeuroOne, Inc. merged with and into NeuroOne. NeuroOne is committed to providing minimally invasive and hi definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. From November 2009 to November 2015, Mr. Rosa served as the Chief Executive Officer and President of Sunshine Heart, Inc., n/k/a CHF Solutions, Inc. (Nasdaq: CHFS), a publicly held early stage medical device company. From 2008 to November 2009, he served as Chief Executive Officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served as the Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. He serves as a director on the board of directors of Biotricity Inc. (Nasdaq:BTCY) and Healthcare Triangle, Inc. (Nasdaq:HCTI). Mr. Rosa previoly served as Chairman of Neuro Event Labs, a privately held company in Finland, and is an Advisory Board member of SYNAPS Dx, a privately held company in Bethesda, Maryland.
- Jason Mills
-
Jason R. Mills，担任在纽约证券交易所上市的Penumbra, Inc.战略执行副总裁，领导长期规划、FP & A、业务发展和投资者关系。Penumbra是世界领先的血栓切除公司，专注于开发最具创新性的技术，以应对缺血性脑卒中、肺栓塞等静脉血栓栓塞以及急性肢体缺血等具有挑战性的医疗条件。在加入Penumbra之前，他是一名敬业的医疗技术投资分析师，时间超过二十年。Mills先生在Canaccord Genuity担任董事总经理和医疗技术股权研究业务负责人超过13年，在那里他准备了财务模型和财务预测，发表了研究报告，并对该行业的数十家公共和私营公司进行了尽职调查。他的股票研究获得了奖项，包括在《华尔街日报》2011年“街头最佳”调查中排名# 2的医疗器械分析师，以及在《福布斯》2010年最佳经纪分析师的医疗产品部分中排名# 1。他拥有耶鲁大学经济学学士学位和俄亥俄大学体育管理硕士学位。
Jason Mills has served as a member of the Board since December 2025. Mr. Mills currently serves as Executive Vice President of Strategy at NYSE listed Penumbra, Inc., leading long range planning, FP&A, Biness Development, and Investor Relations. Penumbra is the world's leading thrombectomy company, foced on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, veno thromboembolism such as pulmonary embolism, and acute limb ischemia. Prior to joining Penumbra, he was a dedicated med tech investment analyst for more than two decades. Mr. Mills held the role of Managing Director and head of the medical technology equity research practice at Canaccord Genuity for over 13 years, where he prepared financial models and financial forecasts, published research, and conducted due diligence on dozens of public and private companies in the sector. He has earned awards for his equity research, including the #2 ranked Medical Devices analyst in The Wall Street Jnal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts. He holds a BA in Economics from Yale University and Masters in Sports Administration from Ohio University. - Jason R. Mills，担任在纽约证券交易所上市的Penumbra, Inc.战略执行副总裁，领导长期规划、FP & A、业务发展和投资者关系。Penumbra是世界领先的血栓切除公司，专注于开发最具创新性的技术，以应对缺血性脑卒中、肺栓塞等静脉血栓栓塞以及急性肢体缺血等具有挑战性的医疗条件。在加入Penumbra之前，他是一名敬业的医疗技术投资分析师，时间超过二十年。Mills先生在Canaccord Genuity担任董事总经理和医疗技术股权研究业务负责人超过13年，在那里他准备了财务模型和财务预测，发表了研究报告，并对该行业的数十家公共和私营公司进行了尽职调查。他的股票研究获得了奖项，包括在《华尔街日报》2011年“街头最佳”调查中排名# 2的医疗器械分析师，以及在《福布斯》2010年最佳经纪分析师的医疗产品部分中排名# 1。他拥有耶鲁大学经济学学士学位和俄亥俄大学体育管理硕士学位。
- Jason Mills has served as a member of the Board since December 2025. Mr. Mills currently serves as Executive Vice President of Strategy at NYSE listed Penumbra, Inc., leading long range planning, FP&A, Biness Development, and Investor Relations. Penumbra is the world's leading thrombectomy company, foced on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, veno thromboembolism such as pulmonary embolism, and acute limb ischemia. Prior to joining Penumbra, he was a dedicated med tech investment analyst for more than two decades. Mr. Mills held the role of Managing Director and head of the medical technology equity research practice at Canaccord Genuity for over 13 years, where he prepared financial models and financial forecasts, published research, and conducted due diligence on dozens of public and private companies in the sector. He has earned awards for his equity research, including the #2 ranked Medical Devices analyst in The Wall Street Jnal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts. He holds a BA in Economics from Yale University and Masters in Sports Administration from Ohio University.
高管简历
中英对照 | 中文 | 英文- Ronald McClurg
Ronald McClurg自2021年1月起担任公司首席财务官。在加入公司之前，McClurg先生于2003年10月至2019年6月担任私人医疗设备制造商Incisive Surgical，Inc.的财务与行政副总裁兼首席财务官。从1997年到2002年，McClurg先生担任Wavecrest Corporation的首席财务官兼财务主管，这是一家私营的半导体行业电子测试仪器制造商。1997年之前，McClurg先生担任几家上市公司的首席财务官，包括Video Sentry Corporation，Insignia Systems, Inc.纳斯达克:ISIG和Orthomet，Inc.目前，他在Biomagnetic Sciences，LLC的董事会任职。
Ronald McClurg has over 30 years of financial leadership experience with public and private companies. Mr. McClurg has served as Chief Financial Officer of NeuroOne Medical Technologies Corp. (Nasdaq: NMTC) since January 2021. Prior to joining NeuroOne, from October 2003 to June 2019, Mr. McClurg served as VP – Finance and Administration and Chief Financial Officer of Incisive Surgical, Inc., a privately held medical device manufacturer. Prior to 2003, Mr. McClurg served as Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately held manufacturer of electronic test instruments for the semiconductor industry, and served as Chief Financial Officer for several publicly held companies, including Video Sentry Corporation, Insignia Systems, Inc. (Nasdaq: ISIG), and Orthomet, Inc. Currently, he serves on the board of governors of Biomagnetic Sciences, LLC and serves as a director and audit committee chair for Biotricity, Inc. (Nasdaq: BTCY). Mr. McClurg holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin — Eau Claire.- Ronald McClurg自2021年1月起担任公司首席财务官。在加入公司之前，McClurg先生于2003年10月至2019年6月担任私人医疗设备制造商Incisive Surgical，Inc.的财务与行政副总裁兼首席财务官。从1997年到2002年，McClurg先生担任Wavecrest Corporation的首席财务官兼财务主管，这是一家私营的半导体行业电子测试仪器制造商。1997年之前，McClurg先生担任几家上市公司的首席财务官，包括Video Sentry Corporation，Insignia Systems, Inc.纳斯达克:ISIG和Orthomet，Inc.目前，他在Biomagnetic Sciences，LLC的董事会任职。
- Ronald McClurg has over 30 years of financial leadership experience with public and private companies. Mr. McClurg has served as Chief Financial Officer of NeuroOne Medical Technologies Corp. (Nasdaq: NMTC) since January 2021. Prior to joining NeuroOne, from October 2003 to June 2019, Mr. McClurg served as VP – Finance and Administration and Chief Financial Officer of Incisive Surgical, Inc., a privately held medical device manufacturer. Prior to 2003, Mr. McClurg served as Chief Financial Officer and Treasurer of Wavecrest Corporation, a privately held manufacturer of electronic test instruments for the semiconductor industry, and served as Chief Financial Officer for several publicly held companies, including Video Sentry Corporation, Insignia Systems, Inc. (Nasdaq: ISIG), and Orthomet, Inc. Currently, he serves on the board of governors of Biomagnetic Sciences, LLC and serves as a director and audit committee chair for Biotricity, Inc. (Nasdaq: BTCY). Mr. McClurg holds a Bachelor of Business Administration degree in accounting from the University of Wisconsin — Eau Claire.
- Mark Christianson
Mark Christianson是该公司的联合创始人，自2019年2月以来一直担任该公司的业务发展总监和医疗销售联络员。此前，他曾担任公司的业务开发和营销副总裁（2017年7月至2019年2月），也曾担任我们的全资子公司NeuroOne，Inc.的销售与市场营销副总裁（2016年12月以来）。2013年5月至2016年12月，Christianson先生担任Cortec Corporation的北美销售经理。从2012年2月到2013年5月，Christianson先生担任Robert Half International NYSE:RHI的业务开发执行官。从2009年5月到2012年2月，Christianson先生担任PMT Corporation的区域销售经理。Christianson先生在明尼阿波利斯的奥格斯堡学院学习会计。Christianson先生为团队带来了15年的高绩效销售、销售管理和项目管理经验。此外，鉴于他在神经系统领域的经验以及他与关键的癫痫意见领袖的密切关系，他还为公司的发展和公司战略做出了贡献。
Mark Christianson is a co founder of the Company and has served as Biness Development Director and Medical Sales Liaison of the Company since February 2019. Previoly, he served as Vice President of Biness Development and Marketing of the Company from July 2017 until February 2019 and served as vice president of sales and marketing of wholly owned subsidiary, NeuroOne, Inc., since December 2016. From May 2013 to December 2016 Mr. Christianson served as North American sales manager for Cortec Corporation. From February 2012 to May 2013 Mr. Christianson held the position of biness development executive for Robert Half International (NYSE: RHI). From May 2009 to February 2012, Mr. Christianson held the position of regional sales manager for PMT Corporation. Mr. Christianson studied accounting at Augsburg College in Minneapolis.- Mark Christianson是该公司的联合创始人，自2019年2月以来一直担任该公司的业务发展总监和医疗销售联络员。此前，他曾担任公司的业务开发和营销副总裁（2017年7月至2019年2月），也曾担任我们的全资子公司NeuroOne，Inc.的销售与市场营销副总裁（2016年12月以来）。2013年5月至2016年12月，Christianson先生担任Cortec Corporation的北美销售经理。从2012年2月到2013年5月，Christianson先生担任Robert Half International NYSE:RHI的业务开发执行官。从2009年5月到2012年2月，Christianson先生担任PMT Corporation的区域销售经理。Christianson先生在明尼阿波利斯的奥格斯堡学院学习会计。Christianson先生为团队带来了15年的高绩效销售、销售管理和项目管理经验。此外，鉴于他在神经系统领域的经验以及他与关键的癫痫意见领袖的密切关系，他还为公司的发展和公司战略做出了贡献。
- Mark Christianson is a co founder of the Company and has served as Biness Development Director and Medical Sales Liaison of the Company since February 2019. Previoly, he served as Vice President of Biness Development and Marketing of the Company from July 2017 until February 2019 and served as vice president of sales and marketing of wholly owned subsidiary, NeuroOne, Inc., since December 2016. From May 2013 to December 2016 Mr. Christianson served as North American sales manager for Cortec Corporation. From February 2012 to May 2013 Mr. Christianson held the position of biness development executive for Robert Half International (NYSE: RHI). From May 2009 to February 2012, Mr. Christianson held the position of regional sales manager for PMT Corporation. Mr. Christianson studied accounting at Augsburg College in Minneapolis.
- Steve Mertens
Steve Mertens自2019年4月起担任公司首席技术官。从2018年9月到2019年4月，Mertens先生是Steve Mertens Consulting，L.L.C.的顾问，他是该公司的负责人兼所有者。从2012年11月至2018年9月，Mertens先生担任Nuvaira Inc.的研究与开发和运营高级副总裁，该公司是一家私营的肺去神经公司，开发用于阻塞性肺疾病的微创产品。在加入Nuvaira之前，Mertens先生担任波士顿科学国际有限公司NYSE:BSX 研究与开发的高级副总裁，指导心脏病学，电生理和外周血管市场的产品开发的广泛技术。他拥有工程学士学位和工商管理硕士学位。目前，他担任the University Enterprise Laboratories的董事会主席。
Steve Mertens has served as Chief Technology Officer of the Company since April 2019. From September 2018 through April 2019, Mr. Mertens was the principal and owner of Steve Mertens Consulting, L.L.C., where he provided new product development engineering support and assessment services to vario clients. From November 2012 through September 2018, Mr. Mertens served as the senior vice president of research and development and operations at Nuvaira Inc., a privately held lung denervation company developing minimally invasive product for obstructive lung diseases. Prior to Nuvaira, Mr. Mertens served as a senior vice president of research and development for Boston Scientific Corporation (NYSE: BSX), guiding a wide range of technologies through product development for the cardiology, electrophysiology and peripheral vascular markets. He holds a bachelor's degree in chemical engineering from the University of Minnesota and a Master's degree in biness administration from the University of St. Thomas. Currently, he serves on the board of directors of the University Enterprise Laboratories.- Steve Mertens自2019年4月起担任公司首席技术官。从2018年9月到2019年4月，Mertens先生是Steve Mertens Consulting，L.L.C.的顾问，他是该公司的负责人兼所有者。从2012年11月至2018年9月，Mertens先生担任Nuvaira Inc.的研究与开发和运营高级副总裁，该公司是一家私营的肺去神经公司，开发用于阻塞性肺疾病的微创产品。在加入Nuvaira之前，Mertens先生担任波士顿科学国际有限公司NYSE:BSX 研究与开发的高级副总裁，指导心脏病学，电生理和外周血管市场的产品开发的广泛技术。他拥有工程学士学位和工商管理硕士学位。目前，他担任the University Enterprise Laboratories的董事会主席。
- Steve Mertens has served as Chief Technology Officer of the Company since April 2019. From September 2018 through April 2019, Mr. Mertens was the principal and owner of Steve Mertens Consulting, L.L.C., where he provided new product development engineering support and assessment services to vario clients. From November 2012 through September 2018, Mr. Mertens served as the senior vice president of research and development and operations at Nuvaira Inc., a privately held lung denervation company developing minimally invasive product for obstructive lung diseases. Prior to Nuvaira, Mr. Mertens served as a senior vice president of research and development for Boston Scientific Corporation (NYSE: BSX), guiding a wide range of technologies through product development for the cardiology, electrophysiology and peripheral vascular markets. He holds a bachelor's degree in chemical engineering from the University of Minnesota and a Master's degree in biness administration from the University of St. Thomas. Currently, he serves on the board of directors of the University Enterprise Laboratories.
- David Rosa
David Rosa，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会提名委员会主席。Rosa先生自2017年7月起担任NeuroOne Medical技术公司（“NeuroOne”）（纳斯达克：NMTC）的首席执行官、总裁和董事，并于2016年10月至2019年12月NeuroOne，Inc.与NeuroOne合并并入NeuroOne期间担任NeuroOne，Inc.的首席执行官和董事。NeuroOne是NeuroOne的全资子公司。NeuroOne致力于为患有癫痫、帕金森病、肌张力障碍、特发性震颤、背部手术失败导致的慢性疼痛和其他相关神经系统疾病的患者提供脑电图记录、脑刺激和消融解决方案的微创和高清晰度解决方案，这些解决方案可能会改善患者的预后并降低手术成本。2009年11月至2015年11月，Rosa先生担任Sunshine Heart，Inc.，n/k/a CHF Solutions，Inc.（纳斯达克：CHFS）的首席执行官兼总裁，这是一家上市的早期医疗设备公司。从2008年到2009年11月，他担任Milksmart公司的首席执行官，该公司是一家专门为动物提供医疗设备的公司。2004年至2008年，罗萨先生在圣犹达医疗公司担任心脏外科和心脏病学全球营销副总裁。他是Biotricity Inc.（纳斯达克：BTCY）和Healthcare Triangle, Inc.（纳斯达克：HCTI）董事会的董事。罗萨先生是芬兰私营公司Neuro Event Labs的董事长，也是马里兰州贝塞斯达私营公司SYNAPS Dx的顾问委员会成员。
David Rosa has served as one of directors and Chair of Board's Nominating Committee since November 2021. Mr. Rosa has served as the Chief Executive Officer, President and a director of NeuroOne Medical Technologies Corporation, or NeuroOne (Nasdaq: NMTC), since July 2017 and served as Chief Executive Officer and a director of NeuroOne, Inc., formerly its wholly owned subsidiary, from October 2016 until December 2019, when NeuroOne, Inc. merged with and into NeuroOne. NeuroOne is committed to providing minimally invasive and hi definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. From November 2009 to November 2015, Mr. Rosa served as the Chief Executive Officer and President of Sunshine Heart, Inc., n/k/a CHF Solutions, Inc. (Nasdaq: CHFS), a publicly held early stage medical device company. From 2008 to November 2009, he served as Chief Executive Officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served as the Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. He serves as a director on the board of directors of Biotricity Inc. (Nasdaq:BTCY) and Healthcare Triangle, Inc. (Nasdaq:HCTI). Mr. Rosa previoly served as Chairman of Neuro Event Labs, a privately held company in Finland, and is an Advisory Board member of SYNAPS Dx, a privately held company in Bethesda, Maryland.- David Rosa，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会提名委员会主席。Rosa先生自2017年7月起担任NeuroOne Medical技术公司（“NeuroOne”）（纳斯达克：NMTC）的首席执行官、总裁和董事，并于2016年10月至2019年12月NeuroOne，Inc.与NeuroOne合并并入NeuroOne期间担任NeuroOne，Inc.的首席执行官和董事。NeuroOne是NeuroOne的全资子公司。NeuroOne致力于为患有癫痫、帕金森病、肌张力障碍、特发性震颤、背部手术失败导致的慢性疼痛和其他相关神经系统疾病的患者提供脑电图记录、脑刺激和消融解决方案的微创和高清晰度解决方案，这些解决方案可能会改善患者的预后并降低手术成本。2009年11月至2015年11月，Rosa先生担任Sunshine Heart，Inc.，n/k/a CHF Solutions，Inc.（纳斯达克：CHFS）的首席执行官兼总裁，这是一家上市的早期医疗设备公司。从2008年到2009年11月，他担任Milksmart公司的首席执行官，该公司是一家专门为动物提供医疗设备的公司。2004年至2008年，罗萨先生在圣犹达医疗公司担任心脏外科和心脏病学全球营销副总裁。他是Biotricity Inc.（纳斯达克：BTCY）和Healthcare Triangle, Inc.（纳斯达克：HCTI）董事会的董事。罗萨先生是芬兰私营公司Neuro Event Labs的董事长，也是马里兰州贝塞斯达私营公司SYNAPS Dx的顾问委员会成员。
- David Rosa has served as one of directors and Chair of Board's Nominating Committee since November 2021. Mr. Rosa has served as the Chief Executive Officer, President and a director of NeuroOne Medical Technologies Corporation, or NeuroOne (Nasdaq: NMTC), since July 2017 and served as Chief Executive Officer and a director of NeuroOne, Inc., formerly its wholly owned subsidiary, from October 2016 until December 2019, when NeuroOne, Inc. merged with and into NeuroOne. NeuroOne is committed to providing minimally invasive and hi definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. From November 2009 to November 2015, Mr. Rosa served as the Chief Executive Officer and President of Sunshine Heart, Inc., n/k/a CHF Solutions, Inc. (Nasdaq: CHFS), a publicly held early stage medical device company. From 2008 to November 2009, he served as Chief Executive Officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served as the Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. He serves as a director on the board of directors of Biotricity Inc. (Nasdaq:BTCY) and Healthcare Triangle, Inc. (Nasdaq:HCTI). Mr. Rosa previoly served as Chairman of Neuro Event Labs, a privately held company in Finland, and is an Advisory Board member of SYNAPS Dx, a privately held company in Bethesda, Maryland.
- Christopher Volker
Christopher Volker，自2023年11月起担任公司首席运营官。在加入公司之前，Volker先生曾担任雅培的商业整合主管，该公司于2023年4月收购了泰尔茂心血管系统系统公司。2017年5月至2023年8月，Volker先生担任泰尔茂心血管系统国际副总裁兼总经理，负责公司的所有国际业务，包括销售、市场营销、培训和教育以及项目管理。从2014年8月到2017年5月，Volker先生在Cardiovascular Systems, Inc.担任企业发展和健康经济与报销副总裁，担任此职务，他领导跨职能团队制定企业战略计划、与分销合作伙伴进行谈判，并制定和实施新技术的报销策略。Volker先生获得了圣约翰大学的经济和管理文学士学位，以及宾夕法尼亚大学沃顿商学院的金融工商管理硕士学位。
Christopher Volker has served as Chief Operating Officer of the Company since November 2023. Prior to joining the Company, Mr. Volker served as Head of Commercial Integration for Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. From May 2017 until Augt 2023, Mr. Volker held the role of Vice President and General Manager, International for Cardiovascular Systems, Inc. and was responsible for all of the company's international biness, including sales, marketing, training and education, and program management. From Augt 2014 until May 2017, Mr. Volker served as Vice President of Corporate Development and Health Economics & Reimbursement at Cardiovascular Systems, Inc. In such capacity, he led cross functional teams in developing corporate strategic plans, negotiations with distribution partners, and developed and implemented reimbursement strategies for new technology. Mr. Volker received a Bachelor of Arts in Economics and Management from St. John's University and a Master of Biness Administration in Finance from The Wharton School at the University of Pennsylvania.- Christopher Volker，自2023年11月起担任公司首席运营官。在加入公司之前，Volker先生曾担任雅培的商业整合主管，该公司于2023年4月收购了泰尔茂心血管系统系统公司。2017年5月至2023年8月，Volker先生担任泰尔茂心血管系统国际副总裁兼总经理，负责公司的所有国际业务，包括销售、市场营销、培训和教育以及项目管理。从2014年8月到2017年5月，Volker先生在Cardiovascular Systems, Inc.担任企业发展和健康经济与报销副总裁，担任此职务，他领导跨职能团队制定企业战略计划、与分销合作伙伴进行谈判，并制定和实施新技术的报销策略。Volker先生获得了圣约翰大学的经济和管理文学士学位，以及宾夕法尼亚大学沃顿商学院的金融工商管理硕士学位。
- Christopher Volker has served as Chief Operating Officer of the Company since November 2023. Prior to joining the Company, Mr. Volker served as Head of Commercial Integration for Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. From May 2017 until Augt 2023, Mr. Volker held the role of Vice President and General Manager, International for Cardiovascular Systems, Inc. and was responsible for all of the company's international biness, including sales, marketing, training and education, and program management. From Augt 2014 until May 2017, Mr. Volker served as Vice President of Corporate Development and Health Economics & Reimbursement at Cardiovascular Systems, Inc. In such capacity, he led cross functional teams in developing corporate strategic plans, negotiations with distribution partners, and developed and implemented reimbursement strategies for new technology. Mr. Volker received a Bachelor of Arts in Economics and Management from St. John's University and a Master of Biness Administration in Finance from The Wharton School at the University of Pennsylvania.
- Emily Johns
Emily Johns自2025年10月起担任公司首席行政官兼总法律顾问，previoly自2025年6月起担任公司总法律顾问。Previoly，她在2021年1月至2025年5月期间担任Honigman LLP的合伙人，并在2017年10月至2020年12月期间担任Honigman LLP的合伙人，在那里她代表了生命科学行业的许多公司。她的职业生涯始于Sullivan & Cromll LLP，在那里她代表上市公司参与证券发行和并购交易。
Emily Johns Ms. Johns has served as Chief Administrative Officer& General Counsel of the Company since October 2025, and previoly served as General Counsel of the Company beginning in June 2025. Previoly, she served as a partner at Honigman LLP from January 2021 through May 2025, and as an associate at Honigman LLP from October 2017 through December 2020, where she represented many companies in the life sciences industry. She began her career at Sullivan & Cromll LLP, where she represented public companies in securities offerings and M&A transactions. She received her J.D. from UCLA School of Law and her bachelor's degree from the University of Michigan.- Emily Johns自2025年10月起担任公司首席行政官兼总法律顾问，previoly自2025年6月起担任公司总法律顾问。Previoly，她在2021年1月至2025年5月期间担任Honigman LLP的合伙人，并在2017年10月至2020年12月期间担任Honigman LLP的合伙人，在那里她代表了生命科学行业的许多公司。她的职业生涯始于Sullivan & Cromll LLP，在那里她代表上市公司参与证券发行和并购交易。
- Emily Johns Ms. Johns has served as Chief Administrative Officer& General Counsel of the Company since October 2025, and previoly served as General Counsel of the Company beginning in June 2025. Previoly, she served as a partner at Honigman LLP from January 2021 through May 2025, and as an associate at Honigman LLP from October 2017 through December 2020, where she represented many companies in the life sciences industry. She began her career at Sullivan & Cromll LLP, where she represented public companies in securities offerings and M&A transactions. She received her J.D. from UCLA School of Law and her bachelor's degree from the University of Michigan.